Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms.

Kim IS, Gao Y, Welte T, Wang H, Liu J, Janghorban M, Sheng K, Niu Y, Goldstein A, Zhao N, Bado I, Lo HC, Toneff MJ, Nguyen T, Bu W, Jiang W, Arnold J, Gu F, He J, Jebakumar D, Walker K, Li Y, Mo Q, Westbrook TF, Zong C, Rao A, Sreekumar A, Rosen JM, Zhang XH.

Nat Cell Biol. 2019 Sep;21(9):1113-1126. doi: 10.1038/s41556-019-0373-7. Epub 2019 Aug 26.

PMID:
31451770
2.

Correction: A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.

Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.

Oncogene. 2019 Mar;38(13):2436. doi: 10.1038/s41388-018-0587-3.

PMID:
30510231
3.

Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression.

Mowery CT, Reyes JM, Cabal-Hierro L, Higby KJ, Karlin KL, Wang JH, Kimmerling RJ, Cejas P, Lim K, Li H, Furusawa T, Long HW, Pellman D, Chapuy B, Bustin M, Manalis SR, Westbrook TF, Lin CY, Lane AA.

Cell Rep. 2018 Nov 13;25(7):1898-1911.e5. doi: 10.1016/j.celrep.2018.10.061.

4.

A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach.

Rousseaux MWC, Vázquez-Vélez GE, Al-Ramahi I, Jeong HH, Bajić A, Revelli JP, Ye H, Phan ET, Deger JM, Perez AM, Kim JY, Lavery LA, Xu Q, Li MZ, Kang H, Kim JJ, Shulman JM, Westbrook TF, Elledge SJ, Liu Z, Botas J, Zoghbi HY.

J Neurosci. 2018 Oct 24;38(43):9286-9301. doi: 10.1523/JNEUROSCI.0254-18.2018. Epub 2018 Sep 24.

5.

A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome.

Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.

Oncogene. 2019 Feb;38(7):913-934. doi: 10.1038/s41388-018-0488-5. Epub 2018 Sep 7. Erratum in: Oncogene. 2018 Dec 3;:.

6.

Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.

Dasgupta S, Rajapakshe K, Zhu B, Nikolai BC, Yi P, Putluri N, Choi JM, Jung SY, Coarfa C, Westbrook TF, Zhang XH, Foulds CE, Tsai SY, Tsai MJ, O'Malley BW.

Nature. 2018 Apr;556(7700):249-254. doi: 10.1038/s41586-018-0018-1. Epub 2018 Apr 3.

7.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

8.

Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns.

Sack LM, Davoli T, Li MZ, Li Y, Xu Q, Naxerova K, Wooten EC, Bernardi RJ, Martin TD, Chen T, Leng Y, Liang AC, Scorsone KA, Westbrook TF, Wong KK, Elledge SJ.

Cell. 2018 Apr 5;173(2):499-514.e23. doi: 10.1016/j.cell.2018.02.037. Epub 2018 Mar 22.

9.

Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Zeid R, Lawlor MA, Poon E, Reyes JM, Fulciniti M, Lopez MA, Scott TG, Nabet B, Erb MA, Winter GE, Jacobson Z, Polaski DR, Karlin KL, Hirsch RA, Munshi NP, Westbrook TF, Chesler L, Lin CY, Bradner JE.

Nat Genet. 2018 Apr;50(4):515-523. doi: 10.1038/s41588-018-0044-9. Epub 2018 Jan 29.

10.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ.

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

11.

TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau.

Rousseaux MW, de Haro M, Lasagna-Reeves CA, De Maio A, Park J, Jafar-Nejad P, Al-Ramahi I, Sharma A, See L, Lu N, Vilanova-Velez L, Klisch TJ, Westbrook TF, Troncoso JC, Botas J, Zoghbi HY.

Elife. 2016 Oct 25;5. pii: e19809. doi: 10.7554/eLife.19809.

12.

Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model.

Lasagna-Reeves CA, de Haro M, Hao S, Park J, Rousseaux MW, Al-Ramahi I, Jafar-Nejad P, Vilanova-Velez L, See L, De Maio A, Nitschke L, Wu Z, Troncoso JC, Westbrook TF, Tang J, Botas J, Zoghbi HY.

Neuron. 2016 Oct 19;92(2):407-418. doi: 10.1016/j.neuron.2016.09.022. Epub 2016 Oct 6.

13.

Erratum: Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.

Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH.

Nat Cell Biol. 2016 Jun 28;18(7):822. doi: 10.1038/ncb3379. No abstract available.

PMID:
27350446
14.

Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.

Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM, Zhang XH.

Nat Cell Biol. 2016 Jun;18(6):632-44. doi: 10.1038/ncb3355. Epub 2016 May 16. Erratum in: Nat Cell Biol. 2016 Jun 28;18(7):822.

15.

Corrigendum: Mutations in the transcriptional repressor REST predispose to Wilms tumor.

Mahamdallie SS, Hanks S, Karlin KL, Zachariou A, Perdeaux ER, Ruark E, Shaw CA, Renwick A, Ramsay E, Yost S, Elliott A, Birch J, Capra M, Gray J, Hale J, Kingston J, Levitt G, McLean T, Sheridan E, Renwick A, Seal S, Stiller C, Sebire N, Westbrook TF, Rahman N.

Nat Genet. 2016 Apr;48(4):473. doi: 10.1038/ng0329-473d. No abstract available.

PMID:
27023775
16.

Mutations in the transcriptional repressor REST predispose to Wilms tumor.

Mahamdallie SS, Hanks S, Karlin KL, Zachariou A, Perdeaux ER, Ruark E, Shaw CA, Renwick A, Ramsay E, Yost S, Elliott A, Birch J, Capra M, Gray J, Hale J, Kingston J, Levitt G, McLean T, Sheridan E, Renwick A, Seal S, Stiller C, Sebire N, Westbrook TF, Rahman N.

Nat Genet. 2015 Dec;47(12):1471-4. doi: 10.1038/ng.3440. Epub 2015 Nov 9. Erratum in: Nat Genet. 2016 Apr;48(4):473.

PMID:
26551668
17.

The spliceosome is a therapeutic vulnerability in MYC-driven cancer.

Hsu TY, Simon LM, Neill NJ, Marcotte R, Sayad A, Bland CS, Echeverria GV, Sun T, Kurley SJ, Tyagi S, Karlin KL, Dominguez-Vidaña R, Hartman JD, Renwick A, Scorsone K, Bernardi RJ, Skinner SO, Jain A, Orellana M, Lagisetti C, Golding I, Jung SY, Neilson JR, Zhang XH, Cooper TA, Webb TR, Neel BG, Shaw CA, Westbrook TF.

Nature. 2015 Sep 17;525(7569):384-8. doi: 10.1038/nature14985. Epub 2015 Sep 2.

18.

A Systematic Analysis of Factors Localized to Damaged Chromatin Reveals PARP-Dependent Recruitment of Transcription Factors.

Izhar L, Adamson B, Ciccia A, Lewis J, Pontano-Vaites L, Leng Y, Liang AC, Westbrook TF, Harper JW, Elledge SJ.

Cell Rep. 2015 Jun 9;11(9):1486-500. doi: 10.1016/j.celrep.2015.04.053. Epub 2015 May 21.

19.

Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, Konecny GE, Winterhoff B, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Tinker AV, Gilks CB, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD.

Oncogene. 2016 Jan 28;35(4):468-78. doi: 10.1038/onc.2015.101. Epub 2015 Apr 20.

20.

The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.

Wang H, Yu C, Gao X, Welte T, Muscarella AM, Tian L, Zhao H, Zhao Z, Du S, Tao J, Lee B, Westbrook TF, Wong ST, Jin X, Rosen JM, Osborne CK, Zhang XH.

Cancer Cell. 2015 Feb 9;27(2):193-210. doi: 10.1016/j.ccell.2014.11.017. Epub 2015 Jan 15.

21.

The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor.

Karlin KL, Mondal G, Hartman JK, Tyagi S, Kurley SJ, Bland CS, Hsu TY, Renwick A, Fang JE, Migliaccio I, Callaway C, Nair A, Dominguez-Vidana R, Nguyen DX, Osborne CK, Schiff R, Yu-Lee LY, Jung SY, Edwards DP, Hilsenbeck SG, Rosen JM, Zhang XH, Shaw CA, Couch FJ, Westbrook TF.

Cell Rep. 2014 Nov 20;9(4):1318-32. doi: 10.1016/j.celrep.2014.10.011. Epub 2014 Nov 6.

22.

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.

Breast Cancer Res. 2014 Sep 11;16(5):430. doi: 10.1186/s13058-014-0430-x.

23.

Tcf3 promotes cell migration and wound repair through regulation of lipocalin 2.

Miao Q, Ku AT, Nishino Y, Howard JM, Rao AS, Shaver TM, Garcia GE, Le DN, Karlin KL, Westbrook TF, Poli V, Nguyen H.

Nat Commun. 2014 Jun 9;5:4088. doi: 10.1038/ncomms5088.

24.

Plk2 regulates mitotic spindle orientation and mammary gland development.

Villegas E, Kabotyanski EB, Shore AN, Creighton CJ, Westbrook TF, Rosen JM.

Development. 2014 Apr;141(7):1562-71. doi: 10.1242/dev.108258. Epub 2014 Mar 5.

25.

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.

Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambs S.

J Clin Invest. 2014 Jan;124(1):398-412. doi: 10.1172/JCI71180. Epub 2013 Dec 9.

26.

RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1.

Park J, Al-Ramahi I, Tan Q, Mollema N, Diaz-Garcia JR, Gallego-Flores T, Lu HC, Lagalwar S, Duvick L, Kang H, Lee Y, Jafar-Nejad P, Sayegh LS, Richman R, Liu X, Gao Y, Shaw CA, Arthur JSC, Orr HT, Westbrook TF, Botas J, Zoghbi HY.

Nature. 2013 Jun 20;498(7454):325-331. doi: 10.1038/nature12204. Epub 2013 May 29.

27.

Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis.

Cheung WK, Zhao M, Liu Z, Stevens LE, Cao PD, Fang JE, Westbrook TF, Nguyen DX.

Cancer Cell. 2013 Jun 10;23(6):725-38. doi: 10.1016/j.ccr.2013.04.009. Epub 2013 May 23.

28.

A role for PVRL4-driven cell-cell interactions in tumorigenesis.

Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, Elledge SJ.

Elife. 2013 Apr 30;2:e00358. doi: 10.7554/eLife.00358.

29.

Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model.

Dave B, Landis MD, Tweardy DJ, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT.

PLoS One. 2012;7(8):e30207. doi: 10.1371/journal.pone.0030207. Epub 2012 Aug 6. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/753d15c8-2321-4dc5-9b84-c47bd1bd1639.

30.

An animal model of MYC-driven medulloblastoma.

Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ.

Cancer Cell. 2012 Feb 14;21(2):155-67. doi: 10.1016/j.ccr.2011.12.021.

31.

A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.

Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF.

Science. 2012 Jan 20;335(6066):348-53. doi: 10.1126/science.1212728. Epub 2011 Dec 8.

32.

Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.

Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF.

Cell. 2011 Mar 4;144(5):703-18. doi: 10.1016/j.cell.2011.02.003.

33.

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo.

Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, Herschkowitz JI, Burrows AE, Ciccia A, Sun T, Schmitt EM, Bernardi RJ, Fu X, Bland CS, Cooper TA, Schiff R, Rosen JM, Westbrook TF, Elledge SJ.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3665-70. doi: 10.1073/pnas.1019736108. Epub 2011 Feb 9.

34.

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ.

Cell. 2009 May 29;137(5):835-48. doi: 10.1016/j.cell.2009.05.006.

35.

CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation.

Mulligan P, Westbrook TF, Ottinger M, Pavlova N, Chang B, Macia E, Shi YJ, Barretina J, Liu J, Howley PM, Elledge SJ, Shi Y.

Mol Cell. 2008 Dec 5;32(5):718-26. doi: 10.1016/j.molcel.2008.10.025.

36.

SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation.

Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN, Liang A, Leng Y, Maehr R, Shi Y, Harper JW, Elledge SJ.

Nature. 2008 Mar 20;452(7185):370-4. doi: 10.1038/nature06780.

37.

Cancer proliferation gene discovery through functional genomics.

Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ.

Science. 2008 Feb 1;319(5863):620-4. doi: 10.1126/science.1149200. Erratum in: Science.2008 Apr 18;320(5874):316.

38.

Dissecting cancer pathways and vulnerabilities with RNAi.

Westbrook TF, Stegmeier F, Elledge SJ.

Cold Spring Harb Symp Quant Biol. 2005;70:435-44. Review.

PMID:
16869781
39.

A genetic screen for candidate tumor suppressors identifies REST.

Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, Depinho RA, Chin L, Elledge SJ.

Cell. 2005 Jun 17;121(6):837-48.

40.

E7 abolishes raf-induced arrest via mislocalization of p21(Cip1).

Westbrook TF, Nguyen DX, Thrash BR, McCance DJ.

Mol Cell Biol. 2002 Oct;22(20):7041-52.

42.

Biology of human papillomaviruses.

McMurray HR, Nguyen D, Westbrook TF, McAnce DJ.

Int J Exp Pathol. 2001 Feb;82(1):15-33. Review.

Supplemental Content

Loading ...
Support Center